Everything below concerns Certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Abbreviated NMN |
| Molecular formula | C11H15N2O8P | Neutral form |
| Molar mass | 334.22 g/mol | Approximate value |
| Appearance | White to off-white powder | Typical solid form |
| Solubility | Water-soluble | May absorb moisture |
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally stored cold, often at minus twenty degrees Celsius or lower, in a desiccated container protected from light. Aqueous solutions tend to be less stable than dry powder because hydrolysis and dephosphorylation can occur, potentially forming nicotinamide riboside or other degradation products. Stress studies may expose samples to heat, acid, base, oxidation, and strong light to identify likely degradation pathways. Results from such studies help define shelf life and handling recommendations, though exact stability depends on formulation and packaging.
Quality control for NMN materials typically includes identity, assay, purity, and impurity profiling. Tests may cover residual solvents, heavy metals, microbial limits, and water content, depending on the intended use and local rules. Impurity profiles can include related substances such as nicotinamide, nicotinamide riboside, and NAD+, which may form during synthesis or storage. Because commercial NMN can be offered as different salts or hydrate forms, a certificate of analysis should state the form and the analytical methods used. Independent verification is relevant because supplement markets vary in testing requirements and enforcement.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Quality control for NMN focuses on identity, purity, residual solvents, heavy metals, and microbial limits. Because the molecule can absorb water, moisture content and packaging are relevant to shelf life. Suppliers may provide certificates of analysis, but independent verification is often needed for research or commercial use. The long-term stability of different crystal forms, salt forms, and formulations is not fully characterized in the public literature. Some degradation products and their effects on product performance remain open questions.
As a commercial ingredient, nicotinamide mononucleotide is commonly supplied as a powder or capsule. Its stability depends on temperature, moisture, pH, and light exposure. Hydrolytic and thermal degradation can increase over time, so manufacturers and laboratories often store material cold and dry. Purity is typically assessed with chromatographic methods, and identity can be confirmed by mass spectrometry. Published stability data for specific finished products remain limited. More data would help define shelf life under real-world conditions.
Analyses on model and non-model eukaryotic proteomes have revealed that LCRs are frequently found in proteins involved in binding of nucleic acids (DNA or RNA), in transcription, receptor activity, development, reproduction and immunity whereas metabolic proteins are depleted of LCRs. A bioinformatics study of the UniProt annotation of LCR containing proteins observed that 44% (9751/22259) of Bacterial and 44% (662/1521) of Archaeal LCRs are detected in proteins of unknown function, however, a significant number of proteins of known function (from many different species), especially those involved in translation and the ribosome, nucleic acid binding, metal-ion binding, and protein folding were also found to contain LCRs.
Heseltine was disappointed not to receive the support of old allies on the second ballot; these included Secretary of State for Defence Tom King (whom he asked in vain to second his nomination, but who was angry at a leadership contest when British troops were soon to go to war in Kuwait and supported Douglas Hurd), Cecil Parkinson and Norman Lamont (who managed John Major's campaign). Over the weekend on 24–25 November, many Conservative MPs were faced with the anger of their local party members who overwhelmingly supported Thatcher but did not at that time have a vote in leadership elections, and opinion polls showed that chancellor John Major would also boost Conservative support if leader (previously Heseltine's unique selling-point). Heseltine had never done much to court support among younger MPs the way Major had, and was seen as aloof even by his own supporters. In the second ballot, a week after the first, Heseltine's vote actually fell to 131 (just over 35%) as some MPs had voted for him in the first ballot as a protest against or to try to oust Thatcher but preferred to vote for other candidates now that they had a wider choice. John Major, with 185 votes, was only two votes short of an overall majority. Heseltine immediately and publicly conceded defeat, announcing that he would vote for Major if the third ballot went ahead (it did not, as Hurd, who had finished a distant third, also conceded).
=== From heavy-chain antibodies === A single-domain antibody can be obtained by immunization of dromedaries, camels, llamas, alpacas or sharks with the desired antigen and subsequent isolation of the mRNA coding for the variable region (VNAR and VHH) of heavy-chain antibodies. Large phage displayed VNAR and VHH single domain libraries were established from nurse sharks and dromedary camels. Screening techniques like phage display and ribosome display help to identify the clones binding the antigen. The single domain antibodies including VNARs can be humanized for clinical applications.
== Selected awards and honors == 2023 Christian B. Anfinsen Award 2021 American Chemical Society Nakanishi Prize 2018 Nirit and Michael Shaoul Fellow, Sackler Institute of Advanced Studies, Tel Aviv University 2016 Fellow of the International Society of Magnetic Resonance (ISMAR) 2014 Günther Laukien Prize, Experimental NMR Conference 2012 Protein Society Irving Sigal Young Investigator Award 2010 Founders Medal, International Council on Magnetic Resonance in Biological Systems 2010 Fellow of the American Association for the Advancement of Science 2003 Pure Chemistry Award, American Chemical Society 2002 Alfred P. Sloan Research Fellow, Sloan Foundation 2001 CAREER Award, National Science Foundation 1999 Beckman Young Investigator Award, Beckman Foundation
Sources: en.wikipedia.org
3K3A-Activated Protein C (3K3A-APC) is an experimental drug for the treatment of stroke developed by ZZ Biotech, a company founded by Berislav Zlokovic. It is a genetically engineered variant of activated protein C designed to reduce anticoagulant activity while preserving its cytoprotective and anti-inflammatory properties. This recombinant protein is created by substituting three lysine residues with alanines, thereby minimizing the risk of bleeding associated with native activated protein C. 3K3A-APC exerts its therapeutic effects by targeting protease-activated receptor 1 (PAR1) pathway. A Phase 3 clinical trial was scheduled to start when the NIH paused the trial on November 16, 2023, due to concerns about falsification of data in the studies supporting the clinical trial. The drug was also being assessed for the treatment of Alzheimer's disease, and is currently being evaluated by Dermatherix for wound care.
A few organoneptunium compounds are known and chemically characterized, although not as many as for uranium due to neptunium's scarcity and radioactivity. The most well known organoneptunium compounds are the cyclopentadienyl and cyclooctatetraenyl compounds and their derivatives. The trivalent cyclopentadienyl compound Np(C5H5)3·THF was obtained in 1972 from reacting Np(C5H5)3Cl with sodium, although the simpler Np(C5H5) could not be obtained. Tetravalent neptunium cyclopentadienyl, a reddish-brown complex, was synthesized in 1968 by reacting neptunium(IV) chloride with potassium cyclopentadienide:
== Adverse effects == In those taking sulphonylureas there is an increased risk of low blood sugar. 3 adverse reactions were seen higher in saxagliptin vs placebo. Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5 mg and More Commonly than in Patients Treated with Placebo.
=== Beginning of hostilities and responsibility === The cables also describe the chronology of events on 7 and 8 August. The cable, sent on 7 August from Tbilisi, described the hostilities which broke out on the evening of 6 August in Avnevi and Nuli as "atypical". The ambassador cited available evidence that South Ossetia was responsible for starting the conflict to which Georgia was reacting. The cable also noted the Georgian evacuation from Nuli on August 7. Later on 7 August, Deputy Foreign Minister Grigol Vashadze reported to the US Ambassador about the casualties among Georgian peacekeepers after 16:00. Vashadze told the Ambassador that "heavy Russian equipment was being moved south from Java - a military base north of the conflict zone, which Georgians have not seen – even in tense times – in the past." Ambassador told on the same day the Foreign Minister and the Deputy Minister of Defense "to remain calm, not overreact". The cable reported that OSCE monitors had reported the Georgian military deployment. When General Marat Kulakhmetov, the head of the Russian peacekeepers in Tskhinvali, met with Temur Iakobashvili, Kulakhmetov said that he "does not control anything" and that the South Ossetians were "shooting at the Georgians behind my back." Tefft wrote on 8 August, "As late as 22:30 Georgian Ministry of Defense and Ministry of Foreign Affairs officials were still hopeful that the unilateral cease-fire announced by President Saakashvili will hold.
==== Stem Cell-Derived Exosomes ==== Recent research suggests that stem cell-derived exosomes could become an alternative to stem cell-based therapy to minimize the limitations associated with traditional stem cell therapy such as immunogenicity and tumorigenic risk.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.
No. NMN is a precursor that can be converted into NAD+, while NAD+ is a dinucleotide coenzyme involved in redox reactions and signaling.
Small amounts have been reported in foods such as edamame, avocado, broccoli, and milk. Dietary amounts are generally much lower than those used in research studies.
Purity is commonly measured by high-performance liquid chromatography with ultraviolet or mass spectrometric detection. Nuclear magnetic resonance can confirm identity and anomeric composition. Water content and residual solvents may be tested separately.